OPINION: Childhood obesity gets a prescriptionand the food sector a warning Fifty-eight per cent of people taking or considering taking GLP-1 drugs said weight loss was their main driver, while 42% said diabetes was their primary reason
Feature: Targets: Semaglutide: GLP-1 Tirzepatide: GLP-1 + GIP Retatrutide: GLP-1 + GIP + Glucagon Max Weight Loss: Semaglutide: ~15% Tirzepatide: ~22% Retatrutide: 24.2%+ Energy Expenditure: Semaglutide: Low Tirzepatide: Moderate Retatrutide: High Muscle Preservation: Semaglutide: Moderate Tirzepatide: Moderate Retatrutide: Better Dosing Frequency: All: Weekly The addition of glucagon receptor activation gives Retatrutide a unique fat-burning advantage, making it ideal for visceral fat reduction and metabolic reset protocols
Her eye doctor recommended that she get an MRI immediately, which revealed that a stroke had occurred behind her right eye
To validate the application of DART-Seq to human islets, islets from a healthy donor were equally divided into 2 samples and each sample was subjected to either DROP-Seq or DART-Seq (Supplemental Figure 2)
Overall, titration schedules and tolerances vary from individual to individual
If patients experience concerning or persistent injection site reactions, they should discuss these with their healthcare provider rather than assuming such reactions are too minor to report
